Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $11
Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowers the price target from $12 to $11.
Stocks · News reference
Larimar Therapeutics Q2 EPS $(0.30) Beats $(0.39) Estimate
Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.39) by 23.08 percent. This is a 26.83 percent increase over losses of $(0.41) per share
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Larimar Therapeutics, Inc. (LRMR)
Filed: 2026-08-04 AccNo: 0001193125-26-331516 Size: 19 MB Item 2.02: Results of Operations and Financial Condition Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
HC Wainwright & Co. Assumes Larimar Therapeutics at Buy, Announces Price Target of $10